An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.

摘要

BACKGROUND: Aspirin desensitization is an effective therapy for moderate-to-severe aspirin-exacerbated respiratory disease (AERD). Desensitization also allows the use of aspirin for secondary cardiovascular prevention. OBJECTIVE: We sought to investigate the cost-effectiveness of aspirin desensitization with subsequent aspirin therapy in patients with AERD. METHODS: The Healthcare Cost and Utilization Project was used, together with average reimbursements from a large Midwestern health care plan, to model the costs of aspirin desensitization for therapeutic and prophylactic use in patients with AERD. Event probabilities were based on the published literature. RESULTS: Ambulatory desensitization for AERD cost Dollars 6768 per quality-adjusted life year (QALY) saved (Dollars 18.54 per additional symptom-free day). Aspirin desensitization for AERD remained cost-effective (